中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Issue 4
Apr.  2016
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2016  >  32(4): 761-763

Efficacy of three liver- protecting drugs commonly used in treatment of drug- induced liver injury: a comparative analysis

DOI: 10.3969/j.issn.1001-5256.2016.04.033

  • Yingcheng People′s Hospital

  • Published Date: 2016-04-20
    Abstract

  • Objective To compare the efficacy of three liver- protecting drugs commonly used in the treatment of drug- induced liver injury. Methods The clinical data of 90 patients with drug- induced liver injury who were treated in Yingcheng People's Hospital from November 2012 to April 2015 were analyzed retrospectively,and according to the drugs administered,they were divided into groups A,B,and C,with 30 patients in each group. The patients in groups A,B,and C were treated with reduced glutathione,polyene phosphatidylcholine injection,and tiopronin injection,respectively. The efficacy,drug cost,and incidence of adverse events were compared between the three groups. An analysis of variance was used for comparison of continuous data between multiple groups,and the LSD t- test was used for comparison of continuous data between any two groups; the chi- square test was used for comparison of categorical data between multiple groups.Results Group A had a significantly higher overall response rate than groups B and C( 90. 0% vs 73. 3% /76. 7%,χ~2= 2. 78 and 3. 75,both P < 0. 05). Group B had a significantly higher drug cost than groups A and C( 316. 12 ± 4. 05 RMB vs 235. 13 ± 2. 90 and 135. 21 ±7. 62 RMB,both P < 0. 01). The incidence of adverse events showed no significant differences between the three groups( P > 0. 05). Conclusion In the clinical treatment of drug- induced liver injury,reduced glutathione has better efficacy compared with polyene phosphatidylcholine and tiopronin,as well as a reasonable cost. Therefore,this drug is preferred in the treatment of this disease.

     

    • FullText(HTML)
    • References(15)
  • [1]CHEN PR,TAN SY.Influence of a combination of various liverprotecting drugs on incidence of drug-induced liver injury[J].Chin J Tuberc Respir Dis,2014,37(1):58-59.(in Chinese)陈品儒,谭守勇.联合不同种类保肝药物对药物性肝损伤发生率的影响[J].中华结核和呼吸杂志,2014,37(1):58-59.
    [2]TIAN YM,DOU LP,YAO S,et al.Protective effect of ademetionine1,4-butanedisulfonate on liver injury caused by chemotherapeutic agents[J].J Exp Hematol,2013,21(5):1305-1308.(in Chinese)田亚敏,窦丽萍,姚盛,等.S-腺苷蛋氨酸对化疗药物性肝损伤防治疗效的观察[J].中国实验血液学杂志,2013,21(5):1305-1308.
    [3]HAWASA UW,SOLIMAN GM,EL-KASSEM LT,et al.A new flavonoid C-glycoside from solanum elaeagnifolium with hepatoprotective and curative activities against paracetamol-induced liver injury in mice[J].Z Naturforsch C,2013,68(1-2):19-28.
    [4]DU H,TANG Z,GE LH,et al.Cost-effectiveness analysis of 3therapeutic schemes in treating antituberculosis drug-induced hepatotoxicity in HIV/TB patients[J].J Clin Pulm Med,2012,17(8):1430-1432.(in Chinese)杜红,汤卓,葛利辉,等.3种用药方案治疗HIV/TB患者抗结核药物性肝损伤成本-效果分析[J].临床肺科杂志,2012,17(8):1430-1432.
    [5]WU S,YUE Y,TIAN H,et al.Carthamus red from carthamus tinctorius L.exerts antioxidant and hepatoprotective effect against CCl(4)-induced liver damage in rats via the Nrf2 pathway[J].JEthnopharmacol,2013,148(2):570-578.
    [6]HUANG GY,WANG YM.Pharmacoeconomic profiles of four hepatoprotective drugs used for the treatment of drug-induced liver injury[J].Chin J Hepatol,2014,22(10):763-768.(in Chinese)黄广宇,王宇明.四种常用保肝药治疗药物性肝损伤的药物经济学分析[J].中华肝脏病杂志,2014,22(10):763-768.
    [7]LAN D,GAN TQ,WANG L,et al.Value of prophylactic liver-protecting treatment for drug-induced liver injury caused by breast cancer chemotherapy[J].J Guangxi Med Univ,2015,32(2):281-283.(in Chinese)蓝东,甘廷庆,王莉,等.预防性保肝对乳腺癌化疗所致药物性肝损伤的应用价值[J].广西医科大学学报,2015,32(2):281-283.
    [8]DONG Y,HUANG J,LIN X,et al.Hepatoprotective effects of yulangsan polysaccharide against isoniazid and rifampicin-induced liver injury in mice[J].J Ethnopharmacol,2014,152(1):201-206.
    [9]ALI H,KABIR N,MUHAMMAD A,et al.Hautriwaic acid as one of the hepatoprotective constituent of dodonaea viscosa[J].Phytomedicine,2014,21(2):131-140.
    [10]LAI RT,WANG H,GUI HL,et al.Clinical and pathological features in 138 cases of drug-induced liver injury[J].Chin J Hepatol,2012,20(3):185-189.(in Chinese)赖荣陶,王晖,桂红莲,等.138例药物性肝损伤患者的临床特征及肝脏组织学改变[J].中华肝脏病杂志,2012,20(3):185-189.
    [11]ARCHANA PR,VEENA G,SIVARAJ N,et al.Andrographis paniculata(burm.f.)wall.ex nees(kalmegh),a traditional hepatoprotective drug from India[J].Genet Resour Crop Evol,2013,60(3):1181-1189.
    [12]JIN G,LANLAN Z,LI C,et al.Pregnancy outcome following loop electrosurgical excision procedure(LEEP)a systematic review and meta-analysis[J].Arch Gynecol Obstet,2014,289(1):85-99.
    [13]TANG LN,LIN F,SHEN Z,et al.Magnesium isoglycyrrhizinate used in the treatment of chemotherapeutic drugs-induced acute liver dysfunction:a phaseⅢclinical trial[J].Tumor,2012,32(9):738-743.(in Chinese)汤丽娜,林峰,沈赞,等.异甘草酸镁治疗抗肿瘤药物引起的急性药物性肝损伤的Ⅲ期临床试验[J].肿瘤,2012,32(9):738-743.
    [14]HUSSAIN L,IKRAM J,REHMAN K,et al.Hepatoprotective effects of Malva sylvestris L.against paracetamol-induced hepatotoxicity[J].Türksh J Biol,2014,38(3):396-402.
    [15]YANG XY,LI Y,LI ZM,et al.Protective effects of liver protective drugs on liver injury induced by anti-tuberculosis drugs[J].The JPract Med,2015,13:2194-2196.(in Chinese)杨雪迎,李艳,李哲明,等.护肝药物预防抗结核药物所致肝损伤的作用[J].实用医学杂志,2015,13:2194-2196.
    • Relative Articles

  • Relative Articles

    [1]Ronglai CAO, Liang ZHU, Zhengping YU, Jinli HE, Youxiang CHEN. Efficacy and safety of endoscopic retrograde cholangiopancreatography during pregnancy and puerperium： A comparative analysis[J]. Journal of Clinical Hepatology, 2023, 39(12): 2885-2893. doi: 10.3969/j.issn.1001-5256.2023.12.020
    [2]Guiqiang WANG. Application and prospect of cell therapy in clinical treatment of liver diseases[J]. Journal of Clinical Hepatology, 2023, 39(5): 1001-1003. doi: 10.3969/j.issn.1001-5256.2023.05.001
    [3]Jialing GUO, Hui LI, Zijian ZENG, Yujing TAO, Haijian DONG. Research advances in nanomedicine in treatment of liver fibrosis[J]. Journal of Clinical Hepatology, 2023, 39(2): 413-418. doi: 10.3969/j.issn.1001-5256.2023.02.026
    [4]Yan WANG, Fujie ZHANG. Research advances in antiviral drugs for the treatment of hepatitis D[J]. Journal of Clinical Hepatology, 2023, 39(4): 776-784. doi: 10.3969/j.issn.1001-5256.2023.04.007
    [5]Suriguga LU, Ting LIU, Dandan ZHU, Sijia YU, Liqing LU, Junjie DING. Research advances in hepatic fibrosis related signal pathways and anti-hepatic fibrosis drugs[J]. Journal of Clinical Hepatology, 2022, 38(5): 1161-1164. doi: 10.3969/j.issn.1001-5256.2022.05.039
    [6]Rui CHEN, Zhixin WANG, Haining FAN, Haijiu WANG. Research advances in the role of lymphocyte activation gene-3 in liver-related diseases[J]. Journal of Clinical Hepatology, 2021, 37(4): 977-981. doi: 10.3969/j.issn.1001-5256.2021.04.056
    [7]Shuai WANG, Yonggui ZHANG, Jiangbin WANG, Yan XU. Effect of statins on the progression and prognosis of chronic liver diseases[J]. Journal of Clinical Hepatology, 2021, 37(3): 721-724. doi: 10.3969/j.issn.1001-5256.2021.03.045
    [8]XU LiJun, AN XiuQin, LI Yue, LIU JinChun. Research advances in the role of myeloid-derived suppressor cells in liver diseases[J]. Journal of Clinical Hepatology, 2020, 36(12): 2851-2855. doi: 10.3969/j.issn.1001-5256.2020.12.045
    [9]Xu Shuai, Zhang LiPing. Research advances in the role of exosomes in non-neoplastic liver diseases[J]. Journal of Clinical Hepatology, 2020, 36(4): 940-943. doi: 10.3969/j.issn.1001-5256.2020.04.052
    [10]Xu JiaMin, Tang YingMei. Current status of research on bile duct lesions and related liver diseases[J]. Journal of Clinical Hepatology, 2019, 35(4): 934-936. doi: 10.3969/j.issn.1001-5256.2019.04.051
    [11]Xu JingChang, Ye Hui, Wang DaSong. Research advances in drugs for the prevention and treatment of gallstones[J]. Journal of Clinical Hepatology, 2018, 34(11): 2453-2457. doi: 10.3969/j.issn.1001-5256.2018.11.041
    [12]Xu Xin, Ji LiSha, Lu LinLin, Chen LiLi, Xin YongNing, Xuan ShiYing. Research advances in the pathogenesis of drug-induced liver injury[J]. Journal of Clinical Hepatology, 2016, 32(2): 382-385. doi: 10.3969/j.issn.1001-5256.2016.02.041
    [13]Hou HuanRong, Shang Jia, Kang Yi, Li YuKui, Ceng YanLi, Ding GangQiang, Mao ZhongShan, Xiao ErHui. Clinical effect of plasma exchange combined with hemofiltration in patients with subacute liver failure induced by antitubercular agents[J]. Journal of Clinical Hepatology, 2016, 32(2): 342-346. doi: 10.3969/j.issn.1001-5256.2016.02.030
    [14]Yang Jun, Yu YaLi, Zheng ZhangQing. Clinical features of drug- induced liver injury and primary biliary cirrhosis: a comparative analysis[J]. Journal of Clinical Hepatology, 2016, 32(4): 728-731. doi: 10.3969/j.issn.1001-5256.2016.04.024
    [15]Dong JinBin, Shi YiHai, Fang WeiBing. Clinical effect of ultrasound-guided injection of lauromacrogol versus anhydrous ethanol as sclerotherapy for simple hepatic cyst:a therapeutic effect analysis and comparative study[J]. Journal of Clinical Hepatology, 2016, 32(6): 1160-1164. doi: 10.3969/j.issn.1001-5256.2016.06.029
    [16]Liu BaoQing, Xu XiuQin, Men SiYe, Yu Wen, Yang ChengCheng, De Ji, Suo LangPingCuo, Chen Jing, Ni MaZhaBa, Dun ZhuCiRen, Wu Wei. Research advances in natural drugs for prevention and treatment of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2016, 32(3): 557-560. doi: 10.3969/j.issn.1001-5256.2016.03.035
    [17]Liang Yuan, Wang ShiMing, Shi ZhenMing. Research advances in application of molecular- targeted therapy for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2016, 32(3): 601-604. doi: 10.3969/j.issn.1001-5256.2016.02.03.045
    [18]Zheng SuJun, Duan ZhongPing. Current Research on acute-on-chronic liver failure: a comparison between Eastern and Western countries[J]. Journal of Clinical Hepatology, 2015, 31(9): 1400-1404. doi: 10.3969/j.issn.1001-5256.2015.09.009
    [19]Zhang RuLing, Lu LunGen. Current situation and future prospect of cholangiopathy[J]. Journal of Clinical Hepatology, 2012, 28(7): 481-483.
    • Supplements(0)
    • Cited By

  • Cited by

    Periodical cited type(8)

    1. 梁晓晓，袁林. 中药治疗对酒精性肝损伤的保护机制研究进展. 现代医学与健康研究电子杂志. 2021(08): 135-138 .
    2. 谭丽娟，徐沛演，李俐. 血清IL-6、TNF-α检测对药物性肝损伤严重程度的预测价值研究. 中国当代医药. 2021(10): 71-74 .
    3. 唐春翊，郑义宏，郑雯. 甘草酸二铵联合还原型谷胱甘肽治疗阿维A导致药物性肝损伤疗效观察. 中国现代医生. 2020(24): 127-130 .
    4. 陈刚，黄杰萍，谭桂燕，居丽晶. 硫普罗宁肠溶胶囊治疗老年抗精神病药物所致肝损伤的效果及护理. 海峡药学. 2019(07): 180-182 .
    5. 张雅昕. 还原型谷胱甘肽与多烯磷脂酰胆碱治疗药物性肝损伤的疗效比较. 航空航天医学杂志. 2019(12): 1450-1452 .
    6. 田艳平，崔向丽，刘丽宏，张长平. 基于决策树模型对我国6种保肝药物治疗药物性肝损伤的成本-效果分析. 中国药物应用与监测. 2018(03): 131-135 .
    7. 韩峰，郑正茂，朱啸峰. 硫普罗宁联合替比夫定对乙肝患者肝纤维化指标及肝功能的影响. 当代医学. 2017(35): 150-152 .
    8. 刘虎军，高莉萍. 3种常用保肝药物治疗药物性肝损伤的临床效果对比. 昆明医科大学学报. 2017(03): 94-97 .

    Other cited types(1)

  • Created with Highcharts 5.0.7Amount of accessChart context menuAbstract Views, HTML Views, PDF Downloads StatisticsAbstract ViewsHTML ViewsPDF Downloads2024-052024-062024-072024-082024-092024-102024-112024-122025-012025-022025-032025-04010203040
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 5.7 %FULLTEXT: 5.7 %META: 88.1 %META: 88.1 %PDF: 6.3 %PDF: 6.3 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 6.0 %其他: 6.0 %其他: 0.8 %其他: 0.8 %Absecon: 0.6 %Absecon: 0.6 %China: 0.5 %China: 0.5 %Falls Church: 0.2 %Falls Church: 0.2 %India: 0.2 %India: 0.2 %Moorveld: 0.5 %Moorveld: 0.5 %[]: 0.5 %[]: 0.5 %上海: 4.4 %上海: 4.4 %中卫: 0.5 %中卫: 0.5 %北京: 13.4 %北京: 13.4 %十堰: 0.2 %十堰: 0.2 %华盛顿: 0.2 %华盛顿: 0.2 %南宁: 0.5 %南宁: 0.5 %吉林: 0.6 %吉林: 0.6 %哥伦布: 0.3 %哥伦布: 0.3 %嘉兴: 0.2 %嘉兴: 0.2 %基辅: 0.3 %基辅: 0.3 %天津: 0.2 %天津: 0.2 %太原: 0.2 %太原: 0.2 %宣城: 0.2 %宣城: 0.2 %常州: 0.2 %常州: 0.2 %平顶山: 0.2 %平顶山: 0.2 %张家口: 2.5 %张家口: 2.5 %成都: 0.6 %成都: 0.6 %扬州: 0.6 %扬州: 0.6 %拉斯维加斯: 0.2 %拉斯维加斯: 0.2 %昆明: 0.8 %昆明: 0.8 %杭州: 0.5 %杭州: 0.5 %榆林: 1.7 %榆林: 1.7 %洛杉矶: 0.2 %洛杉矶: 0.2 %淄博: 0.3 %淄博: 0.3 %深圳: 0.2 %深圳: 0.2 %温州: 0.3 %温州: 0.3 %漯河: 0.2 %漯河: 0.2 %烟台: 0.2 %烟台: 0.2 %牡丹江: 0.2 %牡丹江: 0.2 %盐城: 0.2 %盐城: 0.2 %石家庄: 0.2 %石家庄: 0.2 %秦皇岛: 0.2 %秦皇岛: 0.2 %芒廷维尤: 34.0 %芒廷维尤: 34.0 %芝加哥: 0.3 %芝加哥: 0.3 %莫斯科: 0.9 %莫斯科: 0.9 %衡阳: 0.2 %衡阳: 0.2 %西宁: 17.6 %西宁: 17.6 %赫尔辛基: 0.3 %赫尔辛基: 0.3 %都柏林: 0.2 %都柏林: 0.2 %重庆: 1.9 %重庆: 1.9 %钦州: 0.2 %钦州: 0.2 %锦州: 0.2 %锦州: 0.2 %镇江: 0.3 %镇江: 0.3 %长春: 1.7 %长春: 1.7 %长沙: 1.9 %长沙: 1.9 %长治: 0.2 %长治: 0.2 %阿姆斯特丹: 0.5 %阿姆斯特丹: 0.5 %青岛: 0.2 %青岛: 0.2 %鞍山: 0.2 %鞍山: 0.2 %魁北克: 0.3 %魁北克: 0.3 %其他其他AbseconChinaFalls ChurchIndiaMoorveld[]上海中卫北京十堰华盛顿南宁吉林哥伦布嘉兴基辅天津太原宣城常州平顶山张家口成都扬州拉斯维加斯昆明杭州榆林洛杉矶淄博深圳温州漯河烟台牡丹江盐城石家庄秦皇岛芒廷维尤芝加哥莫斯科衡阳西宁赫尔辛基都柏林重庆钦州锦州镇江长春长沙长治阿姆斯特丹青岛鞍山魁北克

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (559) PDF downloads(183) Cited by(9)
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return